Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 08/20 05:35:08 pm
78.54 EUR   +0.80%
08/17UCB : Transparency notification BlackRock, Inc
AQ
08/16UCB : Transparency notification BlackRock, Inc.
PU
08/16UCB : Threshold crossings
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summaryMarketScreener Strategies
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • The tendency within the weekly time frame is positive above the technical support level at 67.76 EUR
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • With an enterprise value anticipated at 3.2 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
UCB18.68%17 334
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY24.70%183 667
AMGEN13.53%127 784
ABBOTT LABORATORIES13.40%113 540
ELI LILLY AND COMPANY24.97%113 359
SANOFI2.20%104 921
GLAXOSMITHKLINE22.45%102 291
BRISTOL-MYERS SQUIBB COMPAN..-0.64%99 365
ASTRAZENECA16.75%95 530
NOVO NORDISK A/S-7.32%90 949
BAYER-21.07%83 618
CELGENE CORPORATION-13.41%63 563
More Results
Financials (€)
Sales 2018 4 564 M
EBIT 2018 1 122 M
Net income 2018 764 M
Finance 2018 75,5 M
Yield 2018 1,61%
P/E ratio 2018 19,09
P/E ratio 2019 17,61
EV / Sales 2018 3,29x
EV / Sales 2019 3,05x
Capitalization 15 074 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart UCB
Duration : Period : Day
UCB Technical Analysis Chart | MarketScreener
Duration : Period : Week
UCB Technical Analysis Chart | MarketScreener